unicycive therapeutics is passionate about treating kidney diseases with significant unmet medical needs.
Company profile
Ticker
UNCY
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
813638692
UNCY stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
16 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
D
$50.00 mm in equity / options / securities to be acquired, sold $50.00 mm, 25 investors
20 Mar 24
8-K
Unicycive Announces $50 Million Private Placement
14 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Other Events
21 Feb 24
S-8
Registration of securities for employees
8 Dec 23
8-K
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Other Events
23 Oct 23
Latest ownership filings
4
John Townsend
17 Apr 24
4
Douglas Jermasek
17 Apr 24
4
Pramod Gupta
17 Apr 24
4
Shalabh K. Gupta
17 Apr 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
Nantahala Capital Partners Limited Partnership
5 Feb 24
SC 13G
Logos Global Management LP
22 Jan 24
4
Sandeep Laumas
7 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.35 mm | 14.35 mm | 14.35 mm | 14.35 mm | 14.35 mm | 14.35 mm |
Cash burn (monthly) | 1.49 mm | (no burn) | 1.98 mm | 1.65 mm | 1.47 mm | 1.66 mm |
Cash used (since last report) | 9.91 mm | n/a | 13.15 mm | 10.96 mm | 9.80 mm | 11.04 mm |
Cash remaining | 4.44 mm | n/a | 1.19 mm | 3.39 mm | 4.55 mm | 3.31 mm |
Runway (months of cash) | 3.0 | n/a | 0.6 | 2.1 | 3.1 | 2.0 |
Institutional ownership, Q2 2023
25.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 6 |
Closed positions | 6 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 1.22 bn |
Total shares | 8.85 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 3.47 mm | $5.87 mm |
Biotechnology Value Fund L P | 3.47 mm | $5.87 mm |
Rosalind Advisors | 969.48 k | $2.00 mm |
Nantahala Capital Management | 647.42 k | $828.69 mm |
Vanguard | 115.06 k | $147.27 mm |
Geode Capital Management | 66.75 k | $85.44 mm |
STT State Street | 35.04 k | $44.85 mm |
Ground Swell Capital | 20.00 k | $25.60 mm |
Two Sigma Advisers | 15.20 k | $19.46 mm |
Centiva Capital | 15.19 k | $19.44 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Shalabh K. Gupta | Stock Options Common Stock | Grant | Acquire A | No | No | 1.14 | 1,319,583 | 1.50 mm | 6,206,637 |
15 Apr 24 | Douglas Jermasek | Stock Options Common Stock | Grant | Acquire A | No | No | 1.14 | 463,250 | 528.11 k | 1,973,250 |
15 Apr 24 | Pramod Gupta | Stock Options Common Stock | Grant | Acquire A | No | No | 1.14 | 463,250 | 528.11 k | 2,038,112 |
15 Apr 24 | John Townsend | Stock Options Common Stock | Grant | Acquire A | No | No | 1.14 | 228,119 | 260.06 k | 875,309 |
News
Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
15 Apr 24
Piper Sandler Initiates Coverage On Unicycive Therapeutics with Overweight Rating, Announces Price Target of $9
4 Apr 24
CORRECTION: On Friday, Unicycive Therapeutics Reported Q4 EPS Of $(0.22), Which Missed $(0.17) Estimate
1 Apr 24
Unicycive Therapeutics Q4 EPS $(0.35) Misses $(0.17) Estimate
29 Mar 24
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
14 Mar 24
Press releases
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
10 Apr 24
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
25 Mar 24
Unicycive Announces $50 Million Private Placement
14 Mar 24
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
13 Mar 24
Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?
6 Mar 24